E-DRUG: WHO - patent situation of new hepatitis treatments and prequalification
-----------------------------------------------------------------------------------------------
WHO publishes analysis of patent situation of new hepatitis treatments
and expands pre-qualification to hepatitis
Resolution WHA67.6 requested the Director-General to assist Member States in
ensuring equitable access to quality, effective, affordable and safe HCV
treatments. For governments to identify ways of increasing access and
affordability to these treatments, clarity about whether the medicines are
patent protected in the respective countries is needed. To assist countries
in this endeavor, the WHO Secretariat has published an analysis of the
patent situation of seven new hepatitis treatments, including sofosbuvir:
http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/
Expressions of Interest for prequalification
To support national and global efforts to increase access to and the
affordability of HIV and AIDS-related care and treatment, including treatment
for hepatitis B and C, in both mono-infected and HIV co-infected patients,
WHO, together with UNICEF, UNAIDS and UNITAID, invite applicants for
selected pharmaceutical products to submit Expressions of Interest (EOI) for
product evaluation. The EOI includes among other products Sofosbuvir tablet,
400mg Simeprevir capsule, 150mg Ribavirin capsule, 200mg, 400mg, 600mg
http://apps.who.int/prequal/info_press/pq_news_19September2014_EOI-HIV.htm
regards
Dr Peter Beyer
Senior Advisor
Public Health, Innovation and Intellectual Property
World Health Organization
CH - 1211 Geneva 27
Tel: +41 22 791 2507
beyerp@who.int
http://www.who.int/phi